Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase IIa randomized double-blind placebo-controlled trial of intravenous hUC-MSC injection for acute ischemic stroke
CTR20252683Phase 2Active
- Sponsor
- Yinguan Biotech
- Start
- Aug 2025
- Countries
- 1
01
Overview
A Phase 2 trial of human umbilical cord mesenchymal stem cell in ischemic stroke, sponsored by Yinguan Biotech. Started Aug 2025; status: active.
02
Drugs
human umbilical cord mesenchymal stem cell
03
Conditions
ischemic stroke
Beyond the preview
Go deeper on CTR20252683.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20252683.